Drug Trial Radar · NCT02683213
Efficacy of Fluoxetine - a Trial in Stroke
Last checked: Nov 20, 2026Latest source record: Sep 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,500
Actual
Start
Oct 20, 2014
Primary completion
Jun 2020
Study completion Jun 2020
Sponsor
- Lead sponsor
- Karolinska InstitutetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Swedish Research Council; Swedish Heart Lung Foundation; Stroke-Riksförbundet; Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse; Hjärnfonden (The Swedish Brain foundation); The Swedish Medical Association
- First posted
- Feb 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate whether routine administration of fluoxetine 20mg once daily in the 6 months initiated during the acute stroke improves the patient's functional outcome. EFFECTS is an investigator lead Sweden-based, multicenter, parallel group, double blind placebo controlled trial with broad entry criteria and follow up at 6 and 12 months. EFFECTS managed to recruit its anticipated numbers of 1,500 participants between 20th October 2014 and 28th June 2019. Data will be unblinded when the 6-months follow-up is completed, and the primary outcome is due to report on May 2020.
Conditions
- Stroke
Interventions
FluoxetineDrug
Fluoxetine 20mg once daily for 6 months.
PlaceboDrug
Matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional status, measured with the modified Rankin scale.Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Karolinska Institutet
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.